Breast cancer screening programs could reduce both costs and overdiagnosis by focusing on at-risk women, according to a new study published by JAMA Oncology.

Mark McClellan, MD, a former CMS administrator and a former Commissioner of the FDA, was appointed to Cigna’s board of directors, where he will begin his term Dec. 1.

More than half of patients without a breast cancer diagnosis who were self-referred for a second opinion of imaging results received a change in radiologic interpretation, according to research published online June 28 in the Journal of the American College of Radiology.

Health insurance does little to protect low-income families from crippling financial hardship when a relative has atherosclerotic cardiovascular disease (ASCVD), according to a study published July 3 in JAMA Cardiology.

Higher occupancy rates in hospitals don’t necessarily mean more infections. Rather, a facility can have the highest risk for Clostridium difficile infections when capacity was in a Goldilocks zone—not too full, not too empty—between 25 and 75 percent, according to new research from the University of Michigan and RAND Corporation.

A team of researchers has created a virtual reality (VR) environment that allows users to manipulate 3D molecular proteins 10 times faster than with a 2D screen, according to a July 3 article by the New York Times.

Higher occupancy rates in hospitals don’t necessarily mean more infections. Rather, a facility can have the highest risk for Clostridium difficile infections when capacity was in a Goldilocks zone—not too full, not too empty—between 25 and 75 percent, according to new research from the University of Michigan and RAND Corporation.

Imaging leaders can create significant value by implementing incremental innovation at their radiology practices, according to a new study published by Radiology.

The FDA’s rules preventing sexually active gay men from donating blood are discriminatory and based on outdated fears, a physician wrote in an op-ed piece for the Los Angeles Times.

Researchers have developed a method to separate circulating tumor cells (CTCs) from blood samples, enabling “liquid biopsies” that can help diagnosis, prognosis and suggestions for treatment. The technique can separate CTCs from a 7.5-mL vial of blood with at least 86 percent efficiency in less than an hour.